Cargando…
Antidepressants as Autophagy Modulators for Cancer Therapy
Cancer is a major global public health problem with high morbidity. Depression is known to be a high-frequency complication of cancer diseases that decreases patients’ life quality and increases the mortality rate. Therefore, antidepressants are often used as a complementary treatment during cancer...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10673223/ https://www.ncbi.nlm.nih.gov/pubmed/38005316 http://dx.doi.org/10.3390/molecules28227594 |
_version_ | 1785149589465071616 |
---|---|
author | He, Leping Fu, Yuanfeng Tian, Yuxi Wang, Xiaofeng Zhou, Xuejun Ding, Ren-Bo Qi, Xingzhu Bao, Jiaolin |
author_facet | He, Leping Fu, Yuanfeng Tian, Yuxi Wang, Xiaofeng Zhou, Xuejun Ding, Ren-Bo Qi, Xingzhu Bao, Jiaolin |
author_sort | He, Leping |
collection | PubMed |
description | Cancer is a major global public health problem with high morbidity. Depression is known to be a high-frequency complication of cancer diseases that decreases patients’ life quality and increases the mortality rate. Therefore, antidepressants are often used as a complementary treatment during cancer therapy. During recent decades, various studies have shown that the combination of antidepressants and anticancer drugs increases treatment efficiency. In recent years, further emerging evidence has suggested that the modulation of autophagy serves as one of the primary anticancer mechanisms for antidepressants to suppress tumor growth. In this review, we introduce the anticancer potential of antidepressants, including tricyclic antidepressants (TCAs), tetracyclic antidepressants (TeCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine reuptake inhibitors (SNRIs). In particular, we focus on their autophagy-modulating mechanisms for regulating autophagosome formation and lysosomal degradation. We also discuss the prospect of repurposing antidepressants as anticancer agents. It is promising to repurpose antidepressants for cancer therapy in the future. |
format | Online Article Text |
id | pubmed-10673223 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106732232023-11-14 Antidepressants as Autophagy Modulators for Cancer Therapy He, Leping Fu, Yuanfeng Tian, Yuxi Wang, Xiaofeng Zhou, Xuejun Ding, Ren-Bo Qi, Xingzhu Bao, Jiaolin Molecules Review Cancer is a major global public health problem with high morbidity. Depression is known to be a high-frequency complication of cancer diseases that decreases patients’ life quality and increases the mortality rate. Therefore, antidepressants are often used as a complementary treatment during cancer therapy. During recent decades, various studies have shown that the combination of antidepressants and anticancer drugs increases treatment efficiency. In recent years, further emerging evidence has suggested that the modulation of autophagy serves as one of the primary anticancer mechanisms for antidepressants to suppress tumor growth. In this review, we introduce the anticancer potential of antidepressants, including tricyclic antidepressants (TCAs), tetracyclic antidepressants (TeCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine reuptake inhibitors (SNRIs). In particular, we focus on their autophagy-modulating mechanisms for regulating autophagosome formation and lysosomal degradation. We also discuss the prospect of repurposing antidepressants as anticancer agents. It is promising to repurpose antidepressants for cancer therapy in the future. MDPI 2023-11-14 /pmc/articles/PMC10673223/ /pubmed/38005316 http://dx.doi.org/10.3390/molecules28227594 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review He, Leping Fu, Yuanfeng Tian, Yuxi Wang, Xiaofeng Zhou, Xuejun Ding, Ren-Bo Qi, Xingzhu Bao, Jiaolin Antidepressants as Autophagy Modulators for Cancer Therapy |
title | Antidepressants as Autophagy Modulators for Cancer Therapy |
title_full | Antidepressants as Autophagy Modulators for Cancer Therapy |
title_fullStr | Antidepressants as Autophagy Modulators for Cancer Therapy |
title_full_unstemmed | Antidepressants as Autophagy Modulators for Cancer Therapy |
title_short | Antidepressants as Autophagy Modulators for Cancer Therapy |
title_sort | antidepressants as autophagy modulators for cancer therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10673223/ https://www.ncbi.nlm.nih.gov/pubmed/38005316 http://dx.doi.org/10.3390/molecules28227594 |
work_keys_str_mv | AT heleping antidepressantsasautophagymodulatorsforcancertherapy AT fuyuanfeng antidepressantsasautophagymodulatorsforcancertherapy AT tianyuxi antidepressantsasautophagymodulatorsforcancertherapy AT wangxiaofeng antidepressantsasautophagymodulatorsforcancertherapy AT zhouxuejun antidepressantsasautophagymodulatorsforcancertherapy AT dingrenbo antidepressantsasautophagymodulatorsforcancertherapy AT qixingzhu antidepressantsasautophagymodulatorsforcancertherapy AT baojiaolin antidepressantsasautophagymodulatorsforcancertherapy |